

# HSE – Medicines Management Programme (MMP)



The HSE-Medicines Management Programme (MMP) aims to promote safe, effective and cost-effective prescribing in Ireland. Information on MMP initiatives is available on [www.hse.ie/mmp](http://www.hse.ie/mmp)

## HSE-MMP Preferred Drugs

Therapeutic Area	☑ HSE-MMP Preferred Drug
Angiotensin-Converting Enzyme (ACE) Inhibitor	Ramipril
Angiotensin-II Receptor Blocker (ARB)	Candesartan
Beta Blocker	Bisoprolol
Calcium Channel Blocker (CCB)	Amlodipine
Oral Anticoagulant	Warfarin
Direct Oral Anticoagulant (DOAC)	Apixaban
Proton Pump Inhibitor (PPI)	Pantoprazole
Selective Serotonin Reuptake Inhibitor (SSRI)	Sertraline
Serotonin Noradrenaline Reuptake Inhibitor (SNRI)	Venlafaxine
Statin	Atorvastatin
Urology (Urinary incontinence, frequency, overactive bladder)	Tolterodine extended release

### HSE-MMP Preferred Standard Oral Nutritional Supplements (ONS)

**List A:** Powdered ONS (*Aymes Shake/with Fibre, Aymes Shake Compact, Complan Shake, Ensure Shake, Foodlink Complete/with Fibre, Fresubin Powder Extra*) and Compact & Mini Drink sip feeds (*Altraplen Compact, Ensure Compact, Fortisip Compact/with Fibre, Fresubin 2Kcal Mini Drink/with Fibre*).

Standard ONS Prescribing Pathway for Adults Living in the Community is available on [www.hse.ie/mmp](http://www.hse.ie/mmp)

### HSE-MMP Preferred Blood Glucose Test Strips (BGTS)

The HSE-MMP has identified preferred BGTS with associated meters for adults with type 1 and type 2 diabetes mellitus. This list was updated at the beginning of 2023. A list of preferred BGTS with associated meters was identified to ensure that there are a variety of options available to patients and prescribers. The HSE-MMP recognises the potential for a reduction in expenditure on BGTS by increased utilisation of preferred BGTS. Further information is available on [www.hse.ie/mmp](http://www.hse.ie/mmp)

### Prescribing and Cost Guidance: Dry Eye Syndrome

The HSE-MMP has completed a review of the treatment of dry eye syndrome (DES) and published a Prescribing and Cost Guidance document. The guidance document and associated tips and tools recommend first-line preparations based on clinical evidence and cost, and are intended to promote best practice and aid appropriate prescribing for DES. These documents are available on [www.hse.ie/mmp](http://www.hse.ie/mmp)

### HSE-MMP Managed Access Processes

Reimbursement application systems are in place for a number of medicines through PCRS online services, including:

- **Xarelto® (rivaroxaban) 2.5 mg film-coated tablets:** reimbursement is supported for a defined subgroup of patients for prevention of atherothrombotic events in adults with coronary artery disease or symptomatic peripheral artery disease at high risk of ischaemic events, when co-administered with aspirin.
- **Saxenda® (liraglutide) 6 mg/ml solution for injection in pre-filled pen:** reimbursement is supported for a defined subgroup of the licensed population for adults, as an adjunct to a reduced-calorie diet and increased physical activity for weight management, with an initial body mass index of  $\geq 35$  kg/m<sup>2</sup> with prediabetes and high-risk of cardiovascular disease.

Managed access protocols are in place for a number of medicines; these are available under *Managed Access Protocols* at [www.hse.ie/mmp](http://www.hse.ie/mmp)